Objective: To determine whether persistent viral suppression alters cognitive trajectories among HIV-infected (HIV1) women on combination antiretroviral therapy (cART) by investigating performance longitudinally in uninfected (HIV2) and 3 groups of HIV1 women: those with consistent viral suppression after continuous cART use (VS), those without consistent virologic suppression despite continuous cART use (NVS), and those without consistent virologic suppression after intermittent cART use (Int NVS).
HIV penetrates the brain early in the course of infection, 1 and 30% to 60% of people with HIV will develop cognitive impairment (CI). 2 Rates of CI remain frequent among HIV-infected (HIV1) individuals with suppressed plasma HIV RNA (VS) 3, 4 vs HIV-uninfected (HIV2) individuals, suggesting that CI persists despite these lifesaving treatments. 5 Less is known about the patterns of CI in the setting of VS, and few cohorts have the capacity to inform the longitudinal trajectories in VS individuals. Existing literature, including cross-sectional work from the cohort in the current study, 6, 7 is largely informed by the examination of combined samples, including VS and unsuppressed individuals. Such heterogeneity limits the understanding of the burden of disease despite viral suppression and the identification of adjunctive therapies for VS individuals, an expanding population with the introduction of increasingly tolerable medication options.
Here, we examine longitudinal changes in CI using viral suppression and consistency of combination antiretroviral therapy (cART) use to define subgroups of HIV1 women. On the basis of prior findings, [7] [8] [9] we expected that all HIV1 women would show impairment at baseline and over time on global function, learning, attention, and executive function compared to HIV2 women. HIV1 and particularly VS women were also expected to perform worse on neuropsychological measures compared to HIV2 women on learning, memory, and attention. Finally, we expected VS women to perform better on neuropsychological testing and that fewer would meet criteria for impairment compared to HIV1 women not achieving persistent viral control whether consistently or intermittently on cART. 10 and Bacon et al. 11 provide recruitment procedures and eligibility criteria. Compared to women not completing neuropsychological testing at all visits (noncompleters, n 5 607), completers (n 5 932) were less likely to be Hispanic and more likely to smoke, to use marijuana and efavirenz, to be adherent to cART and on antiretroviral therapy (ART) for a longer duration, and to have a lower current CD4 count (table e-1 at Neurology.org).
WIHS was approved by the institutional review board at each site and was compliant with the Health Insurance Portability and Accountability Act. Written consent was obtained from all participants.
Primary exposure variable. CD4 count and plasma HIV RNA were measured concurrently with neuropsychological testing, which was implemented in 2009 and administered biennially. ART history and nadir CD4 count were obtained from chart review and self-report. With the use of Department of Health and Human Services/Kaiser Panel 2008 guidelines, HIV treatment regimens were categorized as cART, suboptimal cART, or no ART. Plasma HIV RNA was classified as below the limits of detection at ,48 cp/mL. These data were used to create 4 groups: VS, HIV1 without consistent plasma viral control ($1 visit with a detectable viral load during study period) despite continuous cART use (NVS), HIV1 without consistent plasma viral control after intermittent cART use (Int NVS), and HIV2. Individuals not falling into 1 of these groups were excluded from analysis. Plasma viral failure was defined as HIV RNA $10,000 cp/mL.
Neuropsychological outcomes. The following assessments were used: learning, Hopkins Verbal Learning Test-Revised (HVLT-R; outcome 5 total learning); memory, HVLT-R (outcome 5 delay free recall); attention/working memory, letter-number sequencing (outcomes 5 experimental and control conditions total correct); executive function, Trail Making Test Part B (outcome 5 time to completion) and Stroop Test Trial 3 (outcome 5 time to completion); psychomotor speed, Symbol Digit Modalities Test (outcome 5 total correct) and Stroop Test Trial 2 (outcome 5 time to completion); fluency, letter (outcome 5 total correct) and semantic (outcome 5 total correct); and motor skills, Grooved Pegboard (outcome 5 time to completion, dominant and nondominant hand). Timed outcomes were log transformed to normalize distributions and reverse scored, so higher equated to better performance.
Similar to other large-scale HIV cohorts 4,12,13 including WIHS, 7, [14] [15] [16] demographically adjusted T scores were derived for each outcome. T scores were used to create domain scores and a global performance score for individuals with data for $4 domains (supplemental material). Impairment was examined with continuous (higher/lower scores) and categorical (scoring in the impaired range) outcomes. To examine impairment continuously, a composite T score was derived by averaging T scores for domains with $2 outcomes. If only 1 test in a domain was completed, the T score for that test was used. We computed binary outcomes (T score ,40) using the Multicenter AIDS Cohort Study (MACS) procedures. 12 Continuous T scores and binary outcomes were examined to compare to previous largescale studies.
Statistical analysis. We conducted mixed-effects regressions in SAS PROC MIXED (version 9.4, SAS Institute Inc, Cary, NC) to examine group differences in performance between the full sample of HIV1 and HIV2, between VS and HIV2, and between VS and the 2 other HIV1 groups defined by cART use and viral suppression status. Mixed-effects regression models were selected to handle repeated measurements nested within individuals and to handle missing data. Primary predictors included cART use and plasma viral suppression status, time (continuous), and the group by time interaction. We included the following covariates: site; enrollment wave; self-reported annual household income (#$12,000, .$12,000, missing); depressive symptoms (Center for Epidemiological Studies Depression Scale $16 cutoff); heavy alcohol use (.7 drinks per week or $4 drinks in 1 sitting); smoking status (within the past week, former, never); marijuana use; crack, cocaine, and/or heroin use (within 6 months of the most recent visit, former, never); and hepatitis C RNA positive. Observations were trimmed (studentized residuals .j4.5j), which was the case for ,1% of observations (4 for motor, 8 for speed). Secondary analyses were conducted in HIV1 women to determine whether HIV2related characteristics predicted performance on binary outcomes (nadir and current CD4 cell count, self-reported AIDS diagnosis, self-reported years on ART and efavirenz use, proportion of total WIHS visits with undetectable HIV RNA, plasma viral failure, and CNS White non-Hispanic 38 (16) 28 (13) 14 (8) 21 (7) Hispanic 39 (16) 47 (21) 27 (16) 60 (20) Other 16 (7) 8 (4) 5 (3) 13 (4) Annual household income <$12,000/y, n (%) 93 (39) 109 (49) 83 (48) 146 (48) 0.16
Current depressive symptoms, n (%) a 62 (26) 72 (33) 59 (34) 88 (29) 0.25
Hepatitis C RNA positive, n (%) 40 (17) 57 (26) 37 (21) 39 (13) 0.001 (30) 100 (45) 91 (53) 149 (50) Former 91 (38) 74 (34) 36 (21) 88 (29) Never 76 (32) 46 (21) 45 (26) 64 (21) Recent heavy alcohol use, n (%) c 32 (13) 28 (13) 37 (21) 70 (23) 0.002
Marijuana use, n (%) ,0.001 (14) 28 (13) 32 (18) 76 (25) Former 131 (55) 140 (64) 106 (62) 163 (54) Never 74 (31) 52 (24) 34 (20) 62 (21) Crack, cocaine, and/or heroin use, n (%) 0.04 Recent 9 (4) 15 (7) 17 ( No. of assessments of HIV RNA £48 cp/mL, n (%) -,0.001
HIV RNA ‡10,000 cp/mL, n (%) -28 (13) 55 ( figure 1, top) . HIV1 women also showed an increased likelihood of scoring in the impaired range on attention/working memory (p ,
Among HIV1 women, a 10% increase in the proportion of WIHS visit being suppressed was associated with a decreased likelihood of scoring in the impaired range on learning (OR 0.89, 95% confidence interval figure 3 ). Each HIV1 subgroup was more likely to be impaired than HIV2 women on attention/working memory (p , 0.05) but not executive function (table e-3). In learning, only Int NVS women were more likely to be impaired than HIV2 women (OR 2.27, 95% confidence interval 1.21-4.27, p 5 0.01). Interactions between HIV serostatus and time were significant for motor skills (p , 0.05).
In secondary sensitivity analyses, age did not alter the pattern of results. Age was not included in primary models as a covariate because age was incorporated into the T score computation.
DISCUSSION Findings from this large-scale, longitudinal study show variation in the pattern of performance by plasma viral suppression status and in Table 2 Estimated group mean T score differences (standard errors) in global neuropsychological function and in each domain at baseline examining impairment continuously and categorically. This study expanded our cross-sectional work 7 and allows direct comparison to previously published large-scale HIV1 cohorts. Within our cohort, the full sample of HIV1 women demonstrated initial and continued impairment compared to HIV2 women on global function. Findings confirm persistent deficits in global function among HIV1 women despite continual plasma viral suppression. In addition, our findings demonstrate the persistence and slow evolution of CI in longterm-treated cART cohorts and in global cohorts despite demographic differences. This persistent impairment also suggests that early intervention for HIV1 women may improve neuropsychological function. While HIV serostatus differences were observed in other domains, the pattern of benefits and decrements varied across metrics. This is not surprising because the use of continuous variables that assess the full spectrum of behavior provides greater statistical power than the comparison of proportions below a chosen cut point with a dichotomous outcome. 19, 20 Despite optimal treatment, VS women demonstrated an initial and continued likelihood of impairment in global function, attention/working memory, and executive function but not learning compared to HIV2 women. VS women also showed an increased likelihood of impairment in motor skills compared to HIV2 women. From the pre-cART to post-cART era, studies in largely male cohorts that used categorical measures report primary deficits in global function, learning, 8, 9 attention, 8 and executive function 9 and show decreased likelihood of impairment in motor skills. 8 These reports, in part, align with our cross-sectional findings 7 and longitudinal analysis in MACS showing no effect on psychomotor speed, 19 but they also demonstrate the need for longitudinal data and subgroup analyses to detect differences in fluency and susceptibility over time on motor skills. Consistent with the finding for motor skills, studies demonstrate subcortical brain atrophy in HIV1 men with predominantly well-controlled immune status and viral loads vs controls. 20 Inconsistencies across studies could be due to differences in sociodemographic characteristics, neuropsychological battery, and outcomes incorporated into domains and/or the degree of cohort viral suppression.
Unexpectedly, VS women had worse scores in attention and fluency when performance was measured continuously compared to NVS women. HIV-related clinical factors eliminated group Figure 3 Longitudinal trajectories of cognitive impairment (estimated probability, SE) by group differences in attention but not in fluency. Although the underlying factors driving this pattern of results are unclear, it is possible that cART itself contributes to brain injury, perhaps through mitochondrial injury. 21, 22 In addition to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz) are associated with CNS symptoms possibly through mitochondrial perturbations [23] [24] [25] or diminished blood-brain barrier integrity. 26 Consistent with these findings, current efavirenz use was associated with poorer fluency, a domain in which VS women performed worse than NVS women. Additional work is needed to disentangle specific cART effects that might provide insights into the pattern of vulnerabilities among VS women. Furthermore, findings underscore the importance of examining HIV1 patients by suppression status. Overlooking this heterogeneity may lead to conclusions less pertinent to treated HIV and yield a less relevant framework for studying mechanisms and adjunctive treatments for HIV1 individuals.
Analyses indicated that the Int NVS group performed worse than other HIV1 subgroups on learning and memory, suggesting that the fluctuation in both treatment and plasma viral suppression is more damaging than simply fluctuation in suppression with persistent cART use. However, it is important to note that at any given time, Int NVS women may have stopped taking cART because they felt healthy or the intermittent use could have been linked to fluctuation in other potentially confounding health-related factors. Sixty-two percent of Int NVS women stated they did not take cART because it was not prescribed, their CD4 count was too high or viral load too low, or they felt healthy. These responses could be taken as an indication of health, although in some cases, not being prescribed ART could be due to detrimental factors such as nonadherence.
The strongest HIV-related predictor of neuropsychological performance was the proportion of time with undetectable viral load. Specifically, we found that an increasing proportion of time with undetectable viral load was associated with improved performance in some domains, an encouraging finding. Potent ARTs with less neurotoxicity may support the protective effects of viral suppression on cognition.
In analyses determining whether HIV1 subgroup differences remained in the domains of learning, memory, attention/working memory, and fluency treated continuously, we found that the most consistent predictor across outcomes was a lifetime AIDS diagnosis. Many studies have shown that a past AIDS diagnosis is one of the greatest vulnerabilities among HIV1 individuals, 27 ,28 a finding that may represent decreased cognitive reserve from irreparable brain injury before cART initiation. Consistent with some studies, 29, 30 we also found nadir CD4 count, years of ART use, plasma viral failure, and efavirenz use to negatively influence performance. Conversely, when CPE scores were averaged, performance was optimized compared to lower or higher CPE score. These findings are consistent with others showing that higher CPE scores are associated with a lower frequency of CI 31, 32 but somewhat inconsistent with reports that more penetrant cART regimens are associated with worse neuropsychological function. 18, 33 The present study has limitations. First, more time points would improve the understanding of cognitive trajectories associated with variations in viral suppression and cART use and determine those showing improvement, persistent decline, and fluctuations over time in global and domain-specific neuropsychological functioning. Nevertheless, with 3 time points over 4 years, we demonstrated specific vulnerabilities among HIV1 women despite consistent viral suppression. Second, we used at-risk HIV2 women as our normativebased sample, which may bias our results to yield an underestimation of the magnitude of group differences. We selected our control group as the comparison because they are similar to our HIV1 participants in ethnic composition, socioeconomic status, and substance use. What highlights the comparability between these 2 groups is that even the HIV2 women demonstrated a decline in scores and an increased risk of CI similar to the HIV1 women in learning, memory, and attention/working memory. If healthier, the HIV2 women would have been expected to demonstrate either improvement (demonstrating practice) or a stable performance over time. HIV2 WIHS women, on average, demonstrate CI compared to demographically adjusted normative standards. 34, 35 HIV2 WIHS participants performed on average 2 SDs below HVLT manual age-adjusted norms of individuals 40 to 49 years of age on learning and memory. Normative standards adjusted for age, education, and race indicate that our HIV2 participants performed 1 SD below published norms 34 on HVLT outcomes. The differences observed between serostatus groups suggest an added cognitive injury and persistent vulnerability despite viral suppression. Future studies comparing WIHS women to all or predominantly male HIV1 cohorts will enable us to assess the magnitude and pattern of impairment in WIHS women vs others and to directly assess sex differences because HIV1 women may be more vulnerable than HIV1 men. 36, 37 Overall, global function, learning, memory, attention/working memory, and fluency continue to be vulnerabilities among HIV1 women, particularly among those who are virally suppressed. Future longer-term studies are needed to confirm these observed patterns and to investigate the neurobiological mechanisms underlying these findings.
